MLN4924 prevents N4BP1 deficiency-driven IL-17 signaling autoactivation and psoriasiform dermatitis progression through blockade of Act1 nuclear localization.
文献摘要
Background Psoriasis is a chronic inflammatory skin disease characterized by aberrant production of IL-17 or autoactivation of IL-17 downstream signaling. Anti-IL-17 antibodies are highly effective for most psoriasis patients, but their efficacy is limited when the disease is driven by downstream signaling events, such as ACT1 mutation or N4BP1 deficiency. MLN4924 is a small‑molecule neddylation inhibitor with promising clinical potential. However, its therapeutic value in psoriasis remains unknown, particularly in the context of N4BP1 loss and ACT1 autoactivation. Methods Inflammatory cellular and mouse models, including IL-17 stimulation, N4BP1 knockout, and Act1 overexpression, were used to evaluate the effect of MLN4924 on the expression of IL-17 downstream target genes. The mechanism of action of MLN4924 was explored by assessing MAPK phosphorylation levels and Act1 subcellular localization. Results N4BP1 deficiency, IL-17 stimulation, or Act1 overexpression all strongly induced activation of IL-17 pathways or overproduction of downstream pro‑inflammatory factors such as CXCL1, CCL20, CCL2, CXCL8, CXCL10, and TNFα. Strikingly, in all models tested, MLN4924 treatment fully blocked the overproduction of these pro‑inflammatory factors. Mechanistic studies revealed that the action of MLN4924 was independent of MAPK inhibition or the neddylation pathway, but instead relied on inhibition of Act1 nuclear localization. In vivo experiments demonstrated that topical application of MLN4924 markedly ameliorated erythema, scaling, and epidermal thickening in the dorsal skin of mice, with particularly pronounced efficacy in N4BP1‑knockout animals. Conclusions MLN4924 fully blocks the overproduction of IL-17-downstream targets driven by ACT1 hyperactivation or N4BP1 deficiency and efficiently alleviates psoriasiform dermatitis progression through inhibition of Act1 nuclear localization.